Summary
FOLD Chart
Avoro Capital Advisors LLC Decreases Stock Holdings in Amicus Therapeutics, Inc. $FOLD
Avoro Capital Advisors LLC reduced its stake in Amicus Therapeutics, Inc. (NASDAQ: FOLD) by 16.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,025,000 shares of the biopharmaceutical company's stock after selling 2,975,000 shares during the period.
Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues
FOLD's Q4 earnings miss, but revenues beat estimates on strong Galafold and Pombiliti sales. The company is set to be acquired by BioMarin for $4.8 billion.
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings?
FOLD heads into Q4 earnings with Galafold driving growth and Pombiliti + Opfolda aiding the top line. BioMarin is set to acquire the company for $4.8 billion.
Amicus Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TMB Timothy M. Bidwell Hazlett, BURT & WATSON Inc. | 1,569 | $17.1 | $17.1 | - | - |
| CE Curtis Ellergodt Rothschild Investment LLC | 532 | $5,476.02 | $5,681.39 | $205.37 | 3.75% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 22 | $0.32 | $0.32 | - | - |
 Farallon Capital Farallon Capital Management LLC | 16,000 | $194,560 | $194,560 | - | - |
 George Soros Soros Fund Management LLC | 5.75M | $82.09M | $81.93M | -$165,701 | -0.2% |
Amicus Therapeutics, Inc. (FOLD) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Amicus Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Bradley L. Campbell CEO | NASDAQ (NMS) Exchange | 03152W109 CUSIP |
| US Country | 499 Employees | - Last Dividend | - Last Split | 31 May 2007 IPO Date |
Overview
Amicus Therapeutics, Inc. is a pioneering biotechnology entity dedicated to the mission of discovering, developing, and delivering medicinal solutions for rare diseases. This company has carved a niche for itself in the healthcare sector by focusing on the unmet medical needs of the rare disease community. Established in 2002 and having its headquarters in Princeton, New Jersey, Amicus Therapeutics has been at the forefront of addressing some of the most challenging and underserved medical conditions. Through its strategic collaborations and license agreements with esteemed institutions like the University of Pennsylvania and industry giants like GlaxoSmithKline, Amicus has expanded its research and development capabilities to include innovative gene therapy products, furthering its commitment to the rare disease community.
Products and Services
-
Galafold
This is an oral precision medicine developed by Amicus Therapeutics for the treatment of adults with a confirmed diagnosis of Fabry disease who have an amenable galactosidase alpha gene variant. Galafold represents a significant advancement in the treatment of this genetic disorder, offering a targeted approach that addresses the underlying cause of the disease.
-
Pombiliti + Opfolda
Designed for the treatment of late onset Pompe disease, Pombiliti + Opfolda is part of Amicus Therapeutics' commitment to broadening its portfolio to address a wider range of rare diseases. This development reflects the company's ongoing efforts and investment in research geared towards improving the quality of life for individuals affected by rare genetic disorders.
